Adaptive Radiotherapy for Cancer

(ART-Hypo Trial)

This trial tests a new method of delivering radiotherapy to individuals with certain cancers, such as prostate or cervical cancer. The focus is on adaptive hypofractionated radiotherapy, which adjusts treatment based on daily imaging to minimize unnecessary radiation to surrounding organs. Researchers aim to determine if this method causes fewer side effects than standard-of-care radiotherapy while maintaining effectiveness. Suitable candidates are those already enrolled in a specific cancer registry and who have consented to be contacted for new trials. The goal is to ensure the new treatment is as safe and effective as traditional methods. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that adaptive hypofractionated radiotherapy (ART) is generally well-tolerated by patients. One study found that this method for prostate cancer carries a low risk of severe side effects. Another study demonstrated that hypofractionated radiotherapy, which involves fewer but stronger doses of radiation, is safe for treating certain oral cancers when combined with good supportive care. Additionally, ART for bladder cancer reduces treatment-related side effects. These findings suggest that ART could safely deliver targeted radiation while minimizing harm to nearby healthy tissues.¹²³⁴⁵

Researchers are excited about Adaptive Hypofractionated Radiotherapy (ART-Hypo) because it offers a tailored approach to cancer treatment that adapts to changes in the tumor and surrounding tissue over time. Unlike the standard-of-care radiotherapy, which delivers a consistent dose across sessions, ART-Hypo uses advanced imaging and software to adjust the radiation dose and target area, potentially enhancing effectiveness and minimizing damage to healthy tissue. This could lead to fewer side effects and improved outcomes for patients, making it a promising development in cancer care.

This trial will compare Adaptive Hypofractionated Radiotherapy (ART-Hypo) with Standard-of-care Radiotherapy. Research has shown that ART can effectively treat cancer while reducing side effects. This radiation therapy uses fewer but stronger doses, which helps control cancer and remains safe for patients. For example, one study found that a weekly treatment plan with very strong doses worked well and was safe for older patients. Another study showed that ART with high-dose radiation achieved high success rates and fewer side effects, particularly for cervical cancer. Overall, ART precisely targets tumors and limits radiation to nearby healthy tissues, making it a promising option for certain cancers.⁶⁷⁸⁹¹⁰